Novo's €1.165 billion Nanexa deal: the €615 million "upfront" figure includes milestones

Novo Nordisk, the maker of Wegovy and Ozempic, has signed a global exclusive license for Swedish company Nanexa's PharmaShell drug-delivery technology, in a deal Nanexa says is worth up to €1.165 billion, or about $1.33 billion at Friday morning's exchange rate. The aim is obesity and diabetes injections given monthly or quarterly rather than weekly.

Nanexa shares, which trade on Nasdaq First North Growth Market in Stockholm, rose more than 150% at Friday's open and were up about 114% by late morning local time, CNBC reported. Novo's U.S.-listed shares were up 0.3% at $38.75 in premarket trading, according to Nasdaq data.

What Novo gets

According to Nanexa's announcement, Novo can use PharmaShell in up to five development programs for certain peptide drugs in obesity, type 2 diabetes and other cardiometabolic diseases. PharmaShell puts an ultra-thin inorganic coating on drug particles, applied by a process called atomic layer deposition, to control how fast the drug is released. Novo will lead global development and commercialization. Nanexa also gets low single-digit royalties on sales of any products that result.

The number most headlines blurred

CNBC described Nanexa as eligible for an upfront payment worth around $700 million. That is not quite what the company said. Nanexa's release reads: "Nanexa is eligible to receive total payments of up to EUR 1.165 billion, including EUR 615 million in upfront payment and development and regulatory milestones." The €615 million, about $701 million, combines the signing payment with payments that depend on the programs clearing development and regulatory hurdles. The release does not say how much of it arrives on signing. The remaining €550 million, about $627 million, is tied to sales milestones.

That distinction is the whole story for a company this small. CNBC reported Nanexa's 2025 revenue at about $3.89 million. A payment that lands this year and one that depends on a drug reaching approval years from now are very different things for a microcap's balance sheet, and the release as published does not let an investor tell them apart.

Why it matters for the obesity-drug race

Dosing frequency is one of the few ways left to differentiate in a market where Novo and Eli Lilly both sell weekly injections. Fewer injections is the pitch: Novo and Nanexa are targeting monthly and quarterly administration. Nanexa signed a license and option agreement with Moderna in 2025, the company said, so Novo is not the first large drugmaker to test the platform.

For Novo, the potential cost is modest against its size, and most of it is contingent on success. For traders in Nanexa, the question after a double in a day is how much of the €615 million is actually cash in hand, which the company has not yet spelled out. Nanexa scheduled a live presentation on the deal for Friday at 11:15 a.m. Central European Time; we had not seen any added detail from it at publication.

Sources: Nanexa AB press release; CNBC; Nasdaq. Dollar figures converted at EUR/USD 1.1402 and are Chronicle calculations. This is market information, not investment advice.